This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fisher-Hoch, S. P.
Right arrow Articles by McCormick, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fisher-Hoch, S. P.
Right arrow Articles by McCormick, J. B.

 Previous Article  |  Next Article 

Journal of Virology, August 2000, p. 6777-6783, Vol. 74, No. 15
0022-538X/00/$04.00+0

Effective Vaccine for Lassa Fever

S. P. Fisher-Hoch,1,* L. Hutwagner,2,dagger B. Brown,3,Dagger and J. B. McCormick1,§

Special Pathogens Branch, Division of Viral1 and Rickettsial Diseases, Biostatistics Branch, Division of Bacterial Diseases2, and Animal Resources Branch, Centers for Disease Control and Prevention, Atlanta, Georgia3

Received 7 February 2000/Accepted 3 May 2000

Lassa fever has been estimated to cause 5,000 deaths annually in West Africa. Recently, war in the zone where Lassa fever is hyperendemic has severely impeded control and treatment. Vaccination is the most viable control measure. There is no correlation between antibody levels and outcome in human patients, and inactivated vaccines produce high titers of antibodies to all viral proteins but do not prevent virus replication and death in nonhuman primates. Accordingly, we vaccinated 44 macaques with vaccinia virus-expressed Lassa virus structural proteins separately and in combination, with the object of inducing a predominantly TH1-type immune response. Following Lassa virus challenge, all unvaccinated animals died (0% survival). Nine of 10 animals vaccinated with all proteins survived (90% survival). Although no animals that received full-length glycoprotein alone had a high titer of antibody, 17 of 19 survived challenge (88%). In contrast, all animals vaccinated with nucleoprotein developed high titers of antibody but 12 of 15 died (20% survival). All animals vaccinated with single glycoproteins, G1 or G2, died, but all those that received both single glycoproteins (G1 plus G2) at separate sites survived, showing that both glycoproteins are independently important in protection. Neither group had demonstrable antibody levels prior to challenge. We demonstrate that in primates, immune responses to epitopes on both glycoproteins are required to protect against lethal challenge with Lassa virus without having untoward side effects and that this protection is likely to be primarily cell mediated. We show that an effective, safe vaccine against Lassa virus can and should be made and that its evaluation for human populations is a matter of humanitarian priority.

* Corresponding author. Present address: Fondation Marcel Mérieux, 17 rue Bourgelat, 69002 Lyon, France. Phone: 33-4-72-40-79-58. Fax: 33-4-72-40-79-50. E-mail: jxsmccormk{at}aol.com.

dagger Present address: EPO/CDC, Atlanta, GA 30333.

Dagger Present address: Division of Animal Welfare, OPRR, NIH, Rockville, MD 20892-7507.

§ Present address: Aventis Pasteur, 69260 Marcy l'Etoile, France.

Journal of Virology, August 2000, p. 6777-6783, Vol. 74, No. 15
0022-538X/00/$04.00+0


This article has been cited by other articles:

  • Baize, S., Marianneau, P., Loth, P., Reynard, S., Journeaux, A., Chevallier, M., Tordo, N., Deubel, V., Contamin, H. (2009). Early and Strong Immune Responses Are Associated with Control of Viral Replication and Recovery in Lassa Virus-Infected Cynomolgus Monkeys. J. Virol. 83: 5890-5903 [Abstract] [Full Text]  
  • Larson, R. A., Dai, D., Hosack, V. T., Tan, Y., Bolken, T. C., Hruby, D. E., Amberg, S. M. (2008). Identification of a Broad-Spectrum Arenavirus Entry Inhibitor. J. Virol. 82: 10768-10775 [Abstract] [Full Text]  
  • Scott, E. P., Aronson, J. F. (2008). Cytokine patterns in a comparative model of arenavirus haemorrhagic fever in guinea pigs. J. Gen. Virol. 89: 2569-2579 [Abstract] [Full Text]  
  • Carrion, R. Jr., Brasky, K., Mansfield, K., Johnson, C., Gonzales, M., Ticer, A., Lukashevich, I., Tardif, S., Patterson, J. (2007). Lassa Virus Infection in Experimentally Infected Marmosets: Liver Pathology and Immunophenotypic Alterations in Target Tissues. J. Virol. 81: 6482-6490 [Abstract] [Full Text]  
  • Botten, J., Alexander, J., Pasquetto, V., Sidney, J., Barrowman, P., Ting, J., Peters, B., Southwood, S., Stewart, B., Rodriguez-Carreno, M. P., Mothe, B., Whitton, J. L., Sette, A., Buchmeier, M. J. (2006). Identification of Protective Lassa Virus Epitopes That Are Restricted by HLA-A2.. J. Virol. 80: 8351-8361 [Abstract] [Full Text]  
  • Lukashevich, I. S., Patterson, J., Carrion, R., Moshkoff, D., Ticer, A., Zapata, J., Brasky, K., Geiger, R., Hubbard, G. B., Bryant, J., Salvato, M. S. (2005). A Live Attenuated Vaccine for Lassa Fever Made by Reassortment of Lassa and Mopeia Viruses. J. Virol. 79: 13934-13942 [Abstract] [Full Text]  
  • Boesen, A., Sundar, K., Coico, R. (2005). Lassa Fever Virus Peptides Predicted by Computational Analysis Induce Epitope-Specific Cytotoxic-T-Lymphocyte Responses in HLA-A2.1 Transgenic Mice. CVI 12: 1223-1230 [Abstract] [Full Text]  
  • Pannetier, D., Faure, C., Georges-Courbot, M.-C., Deubel, V., Baize, S. (2004). Human Macrophages, but Not Dendritic Cells, Are Activated and Produce Alpha/Beta Interferons in Response to Mopeia Virus Infection. J. Virol. 78: 10516-10524 [Abstract] [Full Text]  
  • Baize, S., Kaplon, J., Faure, C., Pannetier, D., Georges-Courbot, M.-C., Deubel, V. (2004). Lassa Virus Infection of Human Dendritic Cells and Macrophages Is Productive but Fails to Activate Cells. J. Immunol. 172: 2861-2869 [Abstract] [Full Text]  
  • Thomas, J. M., Klimstra, W. B., Ryman, K. D., Heidner, H. W. (2003). Sindbis Virus Vectors Designed To Express a Foreign Protein as a Cleavable Component of the Viral Structural Polyprotein. J. Virol. 77: 5598-5606 [Abstract] [Full Text]  
  • Borio, L., Inglesby, T., Peters, C. J., Schmaljohn, A. L., Hughes, J. M., Jahrling, P. B., Ksiazek, T., Johnson, K. M., Meyerhoff, A., O'Toole, T., Ascher, M. S., Bartlett, J., Breman, J. G., Eitzen, E. M. Jr, Hamburg, M., Hauer, J., Henderson, D. A., Johnson, R. T., Kwik, G., Layton, M., Lillibridge, S., Nabel, G. J., Osterholm, M. T., Perl, T. M., Russell, P., Tonat, K., for the Working Group on Civilian Biodefense, (2002). Hemorrhagic Fever Viruses as Biological Weapons: Medical and Public Health Management. JAMA 287: 2391-2405 [Abstract] [Full Text]  
  • Pushko, P., Geisbert, J., Parker, M., Jahrling, P., Smith, J. (2001). Individual and Bivalent Vaccines Based on Alphavirus Replicons Protect Guinea Pigs against Infection with Lassa and Ebola Viruses. J. Virol. 75: 11677-11685 [Abstract] [Full Text]  
  • Oldstone, M. B. A., Lewicki, H., Homann, D., Nguyen, C., Julien, S., Gairin, J. E. (2001). Common Antiviral Cytotoxic T-Lymphocyte Epitope for Diverse Arenaviruses. J. Virol. 75: 6273-6278 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»